PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

acarbose Side Effects

The reactions most often reported to the FDA for acarbose (also sold as Precose), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

3,736
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of acarbose come from 3,736 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 3,736 reports to the FDA Adverse Event Reporting System (FAERS) for acarbose (Precose): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

3,736

Reports Mentioning Death

310

8.3% of reports — not proof the medicine caused the death

Hospitalizations

2,037

54.5% of reports

Top Indication

Diabetes Mellitus

Most Reported Adverse Reactions

HYPOGLYCAEMIA
269
NAUSEA
203
BLOOD GLUCOSE INCREASED
200
DIZZINESS
160
DIARRHOEA
147
DRUG INTERACTION
142
VOMITING
142
ACUTE KIDNEY INJURY
139
FALL
125
ASTHENIA
112
LACTIC ACIDOSIS
107
DYSPNOEA
103
DIABETES MELLITUS INADEQUATE CONTROL
99
PNEUMONIA
99
WEIGHT DECREASED
94
PRURITUS
93
FATIGUE
87
PYREXIA
86

Who Reports Side Effects

Gender Distribution

Female 1,793 (51%)
Male 1,726 (49%)
Unknown 4

Age Distribution

0-17 48 (2%)
18-44 233 (8%)
45-64 949 (33%)
65-74 864 (30%)
75+ 784 (27%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 310 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 45
CARDIAC ARREST 35
ACUTE KIDNEY INJURY 34
PNEUMONIA 30
LACTIC ACIDOSIS 28
DYSPNOEA 22
VOMITING 20
COMPLETED SUICIDE 19
METABOLIC ACIDOSIS 17
TACHYCARDIA 17
HAEMODYNAMIC INSTABILITY 15
HYPERKALAEMIA 15
RESPIRATORY FAILURE 15
ASTHENIA 14
CARDIO-RESPIRATORY ARREST 14
CARDIOGENIC SHOCK 14
CEREBROVASCULAR ACCIDENT 14
DEHYDRATION 14
FALL 14
UNRESPONSIVE TO STIMULI 14

Reactions in Hospitalization Reports

Top reactions in 2,037 reports where hospitalization was an outcome.

Reaction Reports
HYPOGLYCAEMIA 186
BLOOD GLUCOSE INCREASED 117
NAUSEA 117
FALL 104
VOMITING 93
ACUTE KIDNEY INJURY 91
DIZZINESS 91
DRUG INTERACTION 87
LACTIC ACIDOSIS 87
DIARRHOEA 81
PNEUMONIA 81
ASTHENIA 75
DYSPNOEA 69
DIABETES MELLITUS INADEQUATE CONTROL 67
PYREXIA 65
CONSTIPATION 61
HYPERKALAEMIA 60
HYPERTENSION 60
HYPOTENSION 56
DECREASED APPETITE 54

Compare acarbose vs alogliptin →

What the FAERS Data Reveals About acarbose Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 3,736 voluntary reports linked to acarbose and its brand equivalents (Precose), spanning 2004 through 2025. Of those, 310 (8.3%) listed death as an outcome and 2,037 (54.5%) involved hospitalization. The most common indication reported alongside adverse events was Diabetes Mellitus.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 51% were female and 49% male; age distribution skews toward 45-64, with 949 reports in that bracket. The single most reported reaction is hypoglycaemia with 269 submissions, followed by nausea and blood glucose increased.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.